Table 8 Clinical studies related to anti-inflammatory effects of EPCs
From: Anti-inflammatory Prowess of endothelial progenitor cells in the realm of biology and medicine
Authors | Dosage | Method | Condition | Follow-up period | Effects | Refs. |
|---|---|---|---|---|---|---|
Klomp et al. | - | EPC capturing stents | Percutaneous coronary intervention | 18 months | ↓ Intimal hyperplasia | |
Aoki et al. | - | EPC capturing stents | Angina or silent ischemia. | 28 days | ↓Neointimal area and inflammatory response | |
Saito et al. | - | EPC capturing stents | Ischaemic coronary disease | 12 months | ↓Inflammatory and prothrombotic signals | |
Yau et al. | 15 × 106 Mesenchymal Precursor Cells | Intramyocardial | Advanced heart failure | 12 months | ↓ Synthesis of inflammatory cytokines, septicity, hemorrhage and thrombosis | |
Steinhoff et al. | 0.5–5 × 106 CD133/VEGFR-2 EPCs | intramyocardially | Myocardial infarction | 24 months | ↓ inflammatory cytokines, such as IL-6, IP10, and NT-proBNP | |
Zhang et al. | 10 × 106 CD133+ EPCs | intra-arterial | Peripheral arterial disease | 4 weeks | ↓ inflammatory cytokines, such as IL-6 and amputation rate |
